Are Peptides Legal in New Mexico? (2026)

The federal rules that apply in New Mexico, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in New Mexico:

• Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
• Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including New Mexico. The PCAC vote page has every tally.
• GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What New Mexico law adds

New Mexico's controlled-substances law (Controlled Substances Act, NMSA 1978, Sections 30-31-1 to 30-31-41; schedules at 30-31-6 to 30-31-10, supplemented by Board of Pharmacy rule 16.19.20 NMAC) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (codes.findlaw.com)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on New Mexico's schedules or in a New Mexico-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Neither the statutory Schedule III nor the Board of Pharmacy's Schedule III rule lists human growth hormone, somatropin or chorionic gonadotropin; the anabolic steroid entry covers testosterone-related steroids only. HGH is a prescription-only dangerous drug in New Mexico, restricted no further than federal law. (NMSA 1978, Section 30-31-8 (Schedule III) and 16.19.20.67 NMAC) (law.cornell.edu)

Compounded semaglutide and tirzepatide

No New Mexico Board of Pharmacy statement specific to compounded GLP-1 drugs was located. Licensed New Mexico pharmacies follow the federal 503A and 503B rules, under which the shortage exception for semaglutide and tirzepatide has ended.

Clinics, medspas and prescribers

No New Mexico medical board guidance specific to peptide therapy was located. A New Mexico prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in New Mexico

Unscheduled research peptides are not controlled substances, so the possession offence in NMSA 30-31-23 does not reach them; NMSA 26-1-16(E) does make it unlawful to possess any prescription-only dangerous drug that was not dispensed by a practitioner or on a prescription, which could apply to injectable peptides sold as prescription drugs, while research-only vials are mainly a seller-side federal issue. (codes.findlaw.com)

Ordering from a vendor in another state. Almost every research-peptide order into New Mexico is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. The Medical Board's ethics rule (16.10.8.8(L) NMAC) permits treatment during a face-to-face telehealth encounter by videoconference where history, informed consent and a medical record are obtained and a physical exam is recorded or properly waived; prescribing based solely on an online questionnaire is listed as unprofessional conduct. No in-person visit is required before a non-controlled GLP-1 prescription. (srca.nm.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a New Mexico law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Enforcement in New Mexico

• 2025-02-19. New Mexico's attorney general signed the 38-state letter urging the FDA to act against counterfeit and research-only GLP-1 sales. (naag.org)
• 2025-10-31. The New Mexico Department of Justice issued a consumer alert warning that unapproved, compounded or counterfeit GLP-1 weight-loss drugs were being sold by medspas, wellness clinics and online sellers, asking residents to use licensed prescribers and pharmacies and to report sellers to its Consumer Protection Division. A warning, not a case against a named defendant. (nmdoj.gov)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. No New Mexico Board of Pharmacy or Medical Board statement on compounded GLP-1s or research peptides was found. The telehealth rule text dates from 2009 and should be read alongside the newer New Mexico Telehealth Act.

Frequently asked questions

Is BPC-157 legal in New Mexico?

New Mexico has not scheduled BPC-157, so possessing it is not a New Mexico offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in New Mexico?

Yes. The Medical Board's ethics rule (16.10.8.8(L) NMAC) permits treatment during a face-to-face telehealth encounter by videoconference where history, informed consent and a medical record are obtained and a physical exam is recorded or properly waived; prescribing based solely on an online questionnaire is listed as unprofessional conduct. No in-person visit is required before a non-controlled GLP-1 prescription. Compounded versions are no longer covered by the FDA's shortage exception, and the FDA has proposed keeping semaglutide and tirzepatide off the 503B bulks list, so expect availability of compounded product to keep shrinking.

Is HGH legal in New Mexico?

Only with a valid prescription for an approved use. New Mexico does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

• https://codes.findlaw.com/nm/chapter-30-criminal-offenses/nm-st-sect-30-31-1/
• https://www.law.cornell.edu/regulations/new-mexico/N-M-Admin-Code-SS-16.19.20.67
• https://www.srca.nm.gov/parts/title16/16.010.0008.html
• https://codes.findlaw.com/nm/chapter-26-drugs-and-cosmetics/nm-st-sect-26-1-16/
• https://www.naag.org/press-releases/state-and-territory-attorneys-general-urge-fda-to-take-action-against-counterfeit-and-illegally-sold-glp-1-drugs/
• https://nmdoj.gov/press-release/media-alert-the-new-mexico-department-of-justice-urges-community-members-to-be-vigilant-when-seeking-weight-loss-medications/

Every New Mexico fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.